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Abstract
Background: Familial hypercholesterolemia (FH) is one of the commonest monogenic disorders, predominantly
inherited as an autosomal dominant trait. When untreated, it results in early coronary heart disease. The vast
majority of FH remains undiagnosed in Latvia. The identification and early treatment of affected individuals remain
a challenge worldwide. Most cases of FH are caused by mutations in one of four genes, APOB, LDLR, PCSK9, or
LDLRAP1. The spectrum of disease-causing variants is very diverse and the variation detection panels usually used in
its diagnosis cover only a minority of the disease-causing gene variants. However, DNA-based tests may provide an
FH diagnosis for FH patients with no physical symptoms and with no known family history of the disease. Here, we
evaluate the use of targeted next-generation sequencing (NGS) to identify cases of FH in a cohort of patients with
coronary artery disease (CAD) and individuals with abnormal low-density lipoprotein–cholesterol (LDL–C) levels.
Methods: We used targeted amplification of the coding regions of LDLR, APOB, PCSK9, and LDLRAP1, followed by
NGS, in 42 CAD patients (LDL–C, 4.1–7.2 mmol/L) and 50 individuals from a population-based cohort (LDL–C,
5.1–9.7 mmol/L).
Results: In total, 22 synonymous and 31 nonsynonymous variants, eight variants in close proximity (10 bp)
to intron–exon boundaries, and 50 other variants were found. We identified four pathogenic mutations
(p.(Arg3527Gln) in APOB, and p.(Gly20Arg), p.(Arg350*), and c.1706–10G > A in LDLR) in seven patients (7.6 %).
Three possible pathogenic variants were also found in four patients.
Conclusion: NGS-based methods can be used to detect FH in high-risk individuals when they do not meet
the defined clinical criteria.
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Background
Familial hypercholesterolemia (FH) was first described in
1920 [1] and is possibly the most common single-gene
disorder. FH is characterized by elevated low-density lipo-
protein–cholesterol (LDL–C) levels, tendon xanthoma,
and arcus corneae before the age of 45 years. In the
majority of cases, FH is inherited as an autosomal
dominant trait, with a penetrance of almost 100 %
[2]. Based on the Copenhagen General Population
Study, the prevalence of heterozygous FH is about
one in 200 individuals. However, the prevalence varies
from one in 200 to one in 500 individuals, depending
on the population [3]. The homozygous form of FH
is much rarer, occurring in only one in 1,000,000
individuals [4–6].
The accumulation of lipids and lipoproteins in the
plasma is the first key process in the development of
atherosclerotic lesions [7]. Atherosclerosis, its resultant
* Correspondence: ilze@biomed.lu.lv
1Latvian Biomedical Research and Study Center, Ratsupites Street 1, Riga
LV-1067, Latvia
Full list of author information is available at the end of the article
© 2015 Radovica-Spalvina et al. Open Access This article is distributed under the terms of the Creative Commons Attribution
4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Radovica-Spalvina et al. BMC Medical Genetics  (2015) 16:86 
DOI 10.1186/s12881-015-0230-x
coronary artery disease (CAD), and other vascular
diseases are the commonest causes of deaths worldwide
[8], and the early diagnosis of FH patients before the
development of severe complications is crucial to the
commencement of appropriate treatment with lipid-
lowering agents.
The diagnosis of FH is often based on physical signs
(tendon xanthoma or arcus corneae before 45 years of age),
laboratory findings (plasma LDL–C levels), and the
patient’s history of elevated LDL–C and cardiovascu-
lar disease. There are at least three approaches to the
diagnosis of FH based on these signs [9]. However,
the absence of physical symptoms is not sufficient to
reject a diagnosis, because about 50 % of heterozy-
gous FH patients do not display physical signs [10]
and there is often no evidence of premature CAD in
heterozygous FH patients [4, 11]. Moreover, in some
monogenic hypercholesterolemias, lipid plasma levels
are similar to the normal ranges [5]. Therefore, DNA-
based tests are required to confirm a diagnosis of FH.
In majority of FH patients have a defective low-
density lipoprotein receptor (LDLR). This results in the
insufficient uptake of low-density lipoprotein (LDL)
particles by cells and the accumulation of LDL–C in
the plasma [12, 13]. Extremely elevated plasma LDL–C
levels greatly increase the risk (by more than 50 %) of
premature CAD before the age of 55 years [11–14]. Hun-
dreds of LDLR mutations have been reported and many of
them cause FH (http://www.ucl.ac.uk/ldlr/Current/, http://
www.hgmd.org/). A phenotypically similar condition,
familial defective apolipoprotein B (FDB), is caused by
defects in the apolipoprotein B gene (APOB) [12, 15], and
especially by mutations in the LDLR-binding domain of
APOB [14, 16]. These mutations prevent the recognition
of the APOB protein by LDLR, and therefore LDL
particles bound to defective APOB cannot be taken
up by cells. Various mutations in the APOB protein
are related to FDB, most commonly p.(Arg3527Gln)
[15, 17, 18]. Gain-of-function mutations in propro-
tein convertase subtilisin/kexin type 9 (PCSK9) have
been suggested to increase the degradation of LDLR,
reducing the number of LDLR molecules on the cell
surface. This further reduces the uptake of LDL particles
by cells, leading to yet another type of monogenic hyper-
cholesterolemia [13, 19–21]. There is also evidence that
functional mutations in low-density lipoprotein adapter
protein 1 (LDLRAP1) cause a recessive form of FH [22,
23]. The plasma LDL–C levels in these patients tend to be
intermediate compared with those in patients with hetero-
zygous or homozygous familial LDLR deficiency [24]. This
adaptor protein is crucial for the normal assembly of
LDLR-rich coated pits on the cell surface and therefore
for normal LDL particle uptake into the cell by endocyto-
sis [23, 25].
The proportion of patients identified with FH and under
treatment remains very low, and most undiagnosed and
untreated patients are young [13]. Recent findings also
suggest that the prevalence of FH is higher than previously
thought [3]. In this context, DNA-based evidence of func-
tional mutations in the LDLR, APOB, PCSK9, and
LDLRAP1 genes is pivotal to making a correct diagnosis
[26] because the actual prevalence of FH may be underes-
timated with the current diagnostic criteria for FH [3].
We conducted this study to assess the spectrum of
FH-related mutations in a group of individuals that was
selected mainly based on their elevated LDL–C levels,
thus representing a typical population, including many
individuals with undiagnosed FH. Another aim of the
study was to estimate the feasibility of targeted next-
generation sequencing (NGS)-based testing for FH.
Methods
Subjects
We conducted this research using DNA samples from
the Genome Database of the Latvian Population
(LGDB), a government-funded biobank (described briefly
in [27]) that included 25,292 participants in August 2014
(1.3 % of the Latvian population). In the LGDB, 4335
samples included data on total cholesterol (TC), high-
density lipoprotein–cholesterol (HDL–C), LDL-C, and
triglyceride (TG) levels. Two groups of patients were
included in the study. We selected 50 unrelated individ-
uals from the extreme end of the LDL–C spectrum and
designated them the “population group” (POP). In total,
292 individuals had LDL–C levels > 4.9 mmol/L, which
is the cut-off value for LDL-C based on World Health
Organization criteria [11]. In this dataset, 50 samples
from the upper end of the distribution, representing a
range of LDL–C from 5.1 to 9.7 mmol/L, were chosen.
The second group of 42 patients was recruited to the
LGDB from the Latvian Center of Cardiology, the
“CAD” group, during the period to March 2013, specific-
ally for this study. The inclusion criteria for this group
was a history of coronary heart disease (previous myo-
cardial infarction or angina) and/or evidence of coronary
atherosclerosis, established with invasive coronary angi-
ography, and a TC level > 7 mmol/l. All subjects who
gave their consent to participate in the study were
included without further selection. All individuals from
the CAD group underwent lipid-lowering therapy and
highest known LDL-C value independently of pre- or
post- treatment was used for this study. Written
informed consent was obtained from all the participants.
The study protocol was approved by the Central Medical
Ethics Committee of Latvia (protocols nr. 2007 A-7 and
01–29.1/25). Sixteen (17 %) samples were also included
in the previous pilot study, investigated with the same
sequencing panel [28].
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Next-generation sequencing (NGS)
We sequenced all the exons (including the exon–intron
boundaries), and 5′ and 3′ untranslated regions of four
FH-related genes (LDLR, APOB, PCSK9, and LDLRAP1),
with the Life Technologies Ion Torrent™ PGM platform,
which is based on the semiconductor sequencing tech-
nology [29]. For target enrichment, we developed an
AmpliSeq™ assay, using the Ion AmpliSeq™ Designer tool
to custom design the assay primers. The design was
based on the human (Hg19) reference genome and pipe-
line v1.2 to generate 200-bp amplicons. In total, 192
primer pairs were designed and mixed in two pools. The
primer pools were manufactured by Life Technologies
and the theoretical coverage of the regions of interest
was 92.1 %. An Invitrogen Qubit 2.0 fluorometer was
used to normalize the genomic DNA concentrations to
5 ng/μl. A standard barcoded AmpliSeq™ library prepar-
ation protocol, with 10 ng of input DNA (release: 10
September 2012, publication part nr. MAN0006735),
was used to prepare the DNA libraries. The final librar-
ies were quantified and their quality checked on an
Agilent 2100 Bioanalyzer using High Sensitivity DNA
chips (Agilent Technologies). The libraries were diluted
to a concentration of approximately 13 pM and all of
the 16 libraries were pooled to ensure the efficient use
of the Ion chip space. The Ion OneTouch™ 200 Tem-
plate Kit v2 DL (release: 12 September 2012, publication
nr. MAN0006957) was used for template preparation
and emulsion PCR. The Ion PGM™ 200 Sequencing Kit
(release: 26 September 2012, Rev. F, publication nr.
4474246) and the standard sequencing protocol for the
Ion 314™ chip were used for the sequencing procedure.
The predicted average coverage was 30x (according to
the standard AmpliSeq protocol).
Variant detection and analysis
The raw data acquired were aligned to the human refer-
ence genome (Hg19) using the Torrent suite 4.0.2 align-
ment plugin v4.0-r77189. The variant-calling plugin
(variantCaller v4.0-r76860) was used to call and annotate
the detected variations within the sequenced samples.
The Standard–Germ Line–PGM–Low Stringency set-
tings were chosen for the variant-calling plugin, in which
the minimal coverage for calling single-nucleotide
polymorphisms (SNPs) was 6x. All variants called were
visually inspected using the Integrative Genomics Viewer
(IGV) v2.3 software (http://www.broadinstitute.org/
software/igv/download) [30] to filter out possible PCR
errors or false-positive variants caused by imperfec-
tions in the variant-calling plugin algorithms or by
the platform specificity [31].
Variants with minor allele frequencies above 1 %,
according to the 1000 Genomes phase 1 genotype
data from 1094 worldwide individuals (http://
browser.1000genomes.org), were considered nonpatho-
genic. Similarly, all deep intronic variants (more than
10 bp away from exon–intron boundaries), other non-
coding variants, and synonymous variants were excluded
from further analysis. The remaining variants were analyzed
by comparing them with the Human Gene Mutation
Database (HGMD; http://www.hgmd.org/), the Familial
Hypercholesterolemia Variant Database (FHVD; http://
www.ucl.ac.uk/ugi/fh), and scientific publications, for anno-
tation purposes. Annotation in silico was also performed
using tools that predict the functional effects of human
SNPs: PolyPhen-2 v2.2.2r398 [32], SIFT [33], and Mutation
Taster [34]. The variants described as causing FH in the
FHVD, supported by evidence in the literature, were
considered pathogenic (Category 1). Nonsynonymous
variants with unknown or unclear evidence of patho-
genicity, which were identified as damaging by all the
prediction tools, were considered possibly pathogenic
(Category 2). All the remaining variants were classified as
variants of uncertain clinical significance (Category 3). All
the Category 1 and Category 2 variants were directly
sequenced for validation.
Results
For the purposes of this research, we selected 50 patients
who represented the general population, with markedly
elevated LDL–C levels (among these, only one individual
had a prior history of CAD), the POP group, and 42
patients with elevated LDL–C levels and established
CAD, the CAD group. The clinical characteristics of our
cohort are summarized in Table 1.
After sequencing errors caused by PCR mistakes, variants
called due to inadequate variant-calling algorithms near ho-
mopolymers, and strand-specific errors specific to the Ion
Torrent platform [31] were removed, 114 different variants
were detected in the total study group. For three variants,
the alternative allele frequencies were 100 %. These were
assumed to be inappropriately annotated in the reference
genome and were not included in the list of variants [35].
Similarly, synonymous coding variants (n = 22) were not in-
cluded in the list of variants. In total, 31 nonsynonymous
variants, eight variants in close proximity (10 bp) to in-
tron–exon boundaries, and 50 other variants were iden-
tified. Information on all (n = 89) the identified
variants is given in Additional file 1: Table S1. Four FH-
causing variants (Category 1), three possibly pathogenic
variants (Category 2), and eight variants of uncertain sig-
nificance (Category 3) were identified (shown in Table 2).
The target coverage achieved in the regions of interest
was 90.7 % and the mean read depth was 117×.
Four new variants were identified (not reported in
any variant database): one missense change p.(Tyr144His)
(APOB) from Category 2, and two missense changes
p.(Val2095Glu) and p.(Met755Leu) (both in APOB) and
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one variant close to an LDLR splice site (c.2141–9 T >G)
from Category 3. Table 3 shows the individual patients
with Category 1, 2, and 3 variants.
FH-causing mutations were identified in seven pa-
tients (7.6 %) and possibly pathogenic variants were
found in another four patients. No significant difference
between the CAD and POP groups was identified in the
number of variants from Categories 1, 2, or 3. All
Category 1 and Category 2 variants were verified with
direct sequencing.
Discussion
The heterogeneity of FH-causing variants supports the
sequence-based detection of the disease as the primary
Table 1 Clinical characteristics of our study cohort
Variable CAD POP P-value Total
n 42 50 92
Age, years ± SD (min-max) 60.0 ± 12.1 (41–89) 58.6 ± 9.7 (23–78) 0.0017 62.0 ± 11.4 (23–89)
Female gender, % 35.7 68.0 0.0023 52.2
CAD, % 100 2.0 <0.0001 46,7
MI, % 54.8 0.0 <0.0001 25,0
TC level, mmol/L ± SD (min-max) 7.9 ± 0.7 (6.7-10.1) 9.3 ± 1.6 (7.0-14.0) <0.0001 8.7 ± 1.5 (6.7-14.0)
LDL-C level, mmol/L ± SD (min-max) 5.6 ± 0.7 (4.1-7.2) 6.6 ± 1.1 (5.1-9.7) <0.0001 6.2 ± 1.0 (4.1-9.7)
LDL-C > 8.5 mmol/L,n 0 5 0.0238 5
LDL-C 6.5-8.4 mmol/L,n 7 18 0.0343 25
LDL-C 5.0-6.4 mmol/L,n 30 27 0.0855 57
LDL-C 4.0-4.9 mmol/L,n 5 0 0.0235 5
BMI, kg/m2 ± SD (min-max) 28.8 ± 4.6 (16.9-41.5) 28.0 ± 5.8 (16.9-42.6) 0.4647 28.3 ± 5.3 (16.9-42.6)
CAD – coronary artery disease; MI – myocardial infarction; TC – total cholesterol; LDL-C – low density lipoprotein cholesterol; BMI – body mass index; For age, TC,
LDL-C and BMI mean values, ± standard deviations (SD) are given as well as minimal and maximal values in brackets
Table 2 Variants of definite and possible importance found in suspected FH patient cohort of Latvian population
CAT Gene rs code AAF FRQ Variants Description with references
1 APOB rs5742904 T = 0,016 T = 0,001 p.(Arg3527Gln) Hypercholesterolemia [18, 40, 41, 44, 49, 50, 52],
associated with increased LDL-C [51]
1 LDLR rs147509697 A = 0,011 A = 0,001 p.(Gly20Arg) Hypercholesterolaemia, possibly damaging [38],
found in FH patient [39–43], used in LIPOCHIP – FH
diagnosis panel [44]
1 LDLR T = 0,005 p.(Arg350*) Hypercholesterolaemia, truncated peptide
[13, 36, 37, 50]
1 LDLR rs17248882 A = 0,005 A = 0.002 c.1706-10G > A Hypercholesterolaemia? [45, 47], 3’splice acceptor
mutation in intron 11 [46, 48], computed
estimation – outside splicing regulatory regions
[38], found in seven FH patients [40, 49]
2 APOB rs201990496 C = 0,005 A = 0.000 p.(Ser3915Cys) No information found
2 APOB rs151009667 T = 0,011 T = 0.002 p.(Arg1689His) Hypertriglyceridaemia?[53]
2 APOB G = 0,005 p.(Tyr144His) No information found
3 APOB rs72654423 C = 0,005 C = 0.003 p.(Ile4314Val) Found in individuals
with high TG levels [63]
3 APOB rs61743502 G = 0,005 G = 0.003 p.(Val4265Ala) No information found
3 APOB rs1801696 T = 0,016 T = 0.002 p.(Glu2566Lys) Hypertriglyceridaemia?[53]
3 APOB rs72653092 T = 0,011 T = 0.001 p.(Ser2429Thr) Hypertriglyceridaemia?[53]
3 APOB T = 0,005 p.(Val2095Glu) No information found
3 APOB A = 0,005 p.(Met755Leu) No information found
3 APOB rs146152405 A = 0,005 T = 0.001 p.(Arg214Leu) No information found
3 LDLR G = 0,005 c.2141-9 T > G No information found
CAT – our designated category of variant; AAF – alternative allele frequency in our cohort; FRQ – frequency of general population (http://www.ncbi.nlm.nih.gov/);
Variant – amino acid exchange (amino acid numbering according to Human Genome Variation Society [64])
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methodology, and the recent advances in NGS-based
techniques has made them more accessible for use in
diagnostics. However, it is unclear how applicable this
approach is to the identification of individuals with FH
in primary care. In this study, we used our recently
developed AmpliSeq-based assay [28] to test the ability
of this approach to identify FH variants in high-risk
groups from general and disease-specific populations,
primarily selected on the basis of their available clinical
and biochemical data. Therefore, the sole criterion for
inclusion in the POP group was elevated LDL-C levels,
whereas the CAD group was selected based on clinical
or angiographic evidence of CAD and high TC levels
(>7 mmol/l). The two groups showed significant differ-
ences in their LDL–C levels and the presence of CAD or
myocardial infarction. However, the two groups did not
differ in the number of variants identified (regardless of
their proposed functions). We found four pathogenic
FH-causing mutations in 7.6 % of the total group of
subjects tested. The LDLR-protein-terminating mutation
p.Arg350* was found in one subject. This variant has
previously been reported as an FH-causing variant in 13
unrelated FH patients [13, 36, 37]. It encodes a
truncated version of the protein, a nonfunctional LDLR,
and therefore reduces the uptake of LDL particles in the
liver and other tissues. p.(Gly20Arg) in LDLR was found
in two patients and has previously been identified in FH
patients in many studies [38–43]. Although it was
predicted to be a benign variant by PolyPhen-2, LDLR
p.(Gly20Arg) is already used in the LIPOchip®–FH diag-
nostic panel [44] and is a confirmed FH-causing variant.
Similarly, c.1706 –10G > A in LDLR was identified by us
in one patient, has been previously and repeatedly
detected in FH patients [40, 45–49]; it is also used in an
FH diagnostic panel [49]. Another variant, p.(Arg3527Gln)
in APOB, was found in three subjects, and is the most
common FH-causing mutation, supported by much epi-
demiological and functional evidence [18, 41, 50–52].
Interestingly, another APOB variant, p.(Glu2566Lys), was
found in all three subjects, suggesting strong linkage
disequilibrium between these variants.
Another three rare APOB mutations were suggested
to be potentially damaging, in terms of the protein
function, by all the prediction tools used in this study.
One of these, p.(Arg1689His), has been described in the
HGMD database as possibly causing hypertriglyceridemia.
Table 3 Individual patients with Category 1, 2 and 3 variants
Patient CAT Group Age Sex LDL-C level, mmol/L Gene ID AA PolyPhen-2 SIFT Mutation taster
4 1 POP 49 M 5,92 LDLR c.1706-10G > A - - N
16 1 POP 62 M 8,15 APOB p.(Arg3527Gln) D D/T D
3 APOB p.(Glu2566Lys) B/D D/T N
33 1 CAD 82 M 4,80 LDLR p.(Gly20Arg) B D/T N
52 1 CAD 81 M 7,16 LDLR p.(Gly20Arg) B D/T N
62 1 POP 23 F 6,23 LDLR p.(Arg350*) - D D
73 1 POP 65 F 7,56 APOB p.(Arg3527Gln) D D/T D
3 APOB p.(Glu2566Lys) B/D D/T N
3 APOB p.(Val2095Glu) B D N
85 1 POP 57 F 6,65 APOB p.(Arg3527Gln) D D/T D
3 APOB p.(Glu2566Lys) B/D D/T N
14 2 CAD 57 M 6,60 APOB p.(Arg1689His) D D D
25 2 CAD 58 F 5,90 APOB p.(Tyr144His) P D D
32 2 CAD 66 M 5,28 APOB p.(Ser3915Cys) P/D D D
123 2 POP 48 M 5,89 APOB p.(Arg1689His) D D D
11 3 CAD 73 M 5,10 APOB p.(Arg214Leu) P D/T N
12 3 CAD 62 M 6,06 APOB p.(Ser2429Thr) B T N
30 3 CAD 59 F 5,76 APOB p.(Ser2429Thr) B T N
42 3 POP 65 M 5,16 APOB p.(Val4265Ala) B D N
56 3 CAD 61 M 5,17 APOB p.(Met755Leu) B T N
90 3 POP 61 F 6,51 APOB p.(Ile4314Val) B D/T N
118 3 POP 58 F 5,95 LDLR c.2141-9 T > G - - D
CAT – ours designated category of variant; M – male; F – female; LDL-C – low density lipoprotein cholesterol; AA – amino acid exchange (amino acid numbering
according to Human Genome Variation Society [64]); D – probably damaging/damaging; P – possibly damaging; B – benign, T – tolerated; N – polymorphism
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However, this variant has also been reported in control
subjects [53], suggesting that it only moderately influences
the FH phenotype. The other two rare variants of APOB,
which have not been described previously, were found in
two (2.2 %) subjects. In addition to the variants described
above, we found seven rare (<1 % according to the 1000
Genomes phase 1 genotype data from 1094 individuals
worldwide; http://browser.1000genomes.org) nonsynon-
ymous variants of unknown clinical significance (Category
3). All nonsynonymous variants in Category 3 were located
in the APOB gene. Apart from p.(Glu2566Lys) which is in
LD with the pathogenic mutation p.(Arg3527Gln), only
p.(Ser2429Thr) has been reported in relation to hypertri-
glyceridemia [53]. Three variants of APOB, p.(Val4265Ala),
p.(Arg214Leu), and p.(Ile4314Val), are reported in the SNP
databases, whereas two other variants of APOB,
p.(Val2095Glu) and p.(Met755Leu), are new and have not
been reported previously. The regions defined by amino
acids 3174–3184 and 4181–4540 of APOB are important
for the correct folding of the protein [54], suggesting that
variants p.(Val4265Ala) and p.(Ile4314Val) detected in our
study are very probably related to the FH phenotype.
However, variants in other exons of the APOB gene, apart
from its functional domains, are also known to be poten-
tially pathogenic [55], so p.(Arg214Leu), p.(Met755Leu),
p.(Val2095Glu), and p.(Ser2429Thr) may also be patho-
genic. We also found one new variant located close to the
LDLR donor splice site of exon 15 (c.2141–9 T >G). Cat-
egory 3 variants were identified in 11 patients, representing
12.0 % of the variants from all subjects (Table 3). It should
be noted that to assess the possible functions of the Cat-
egory 2 and 3 variants, additional functional and segrega-
tion studies will be required to determine the pathogenicity
of these variants. However, for variants with low pene-
trance, which is attributed to the APOB variants, this can
be a difficult task and the challenge of interpreting rare var-
iants identified with NGS is the main obstacle to the intro-
duction of this technique to clinical diagnostics. In addition
to rare variants, we also detected a number of common
polymorphisms, including nonsynonymous variants that
have been associated with elevated LDL–C, atherosclerosis,
and other conditions (summarized in Additional file 1:
Table S1). The extent to which the presence of these
common variants influences the outcomes of patients
with rare low-penetrance variants is unclear.
One of our aims in this project was to compare two
groups that may be representative of populations of
undiagnosed FH patients: the POP group, representing
the general population, but with markedly elevated
LDL–C levels, and the CAD group, representing coron-
ary atherosclerosis patients, the majority of whom are
on lipid-lowering therapy. Therefore, we did not attempt
to control for equal LDL–C levels between the two
groups. Our study group does not represent a typical FH
cohort because no data were collected on their clinical
phenotypes, including their tendon xanthomata (in the
POP group), and no such phenotypes were observed (in
the CAD group). Although some family histories were
collected, they did not provide sufficient details to apply
the commonly used FH criteria to define the disease.
Another relevant consideration was the advanced age of
most of the subjects included in the study, which may
have caused variants with strong effects to be underrepre-
sented. Thus, the pathogenic LDLR mutation p.(Arg350*),
resulting in a nonfunctional protein, was identified in a
23-year-old patient, whereas the APOB variants known for
their moderate effects were found in three patients aged
57–65 years. It is also well known that combinations of
risk alleles of several small effect SNPs, can increase
LDL–C levels [56–58]. Therefore, it cannot be excluded
that LDL–C levels, the main selection criterion, were
influenced by these SNPs in our cohort. Even more
interesting is how these SNPs modify the LDL–C levels
in patients with a monogenic background. However,
much larger cohorts will be required to study the role
of SNPs with sufficient statistical power. The main
difference between the two groups was the presence of
CAD in one of them. An increased prevalence of FH-
related variants could be expected in the CAD group.
However, we observed no significant differences in the
numbers of subjects with Category 1, 2, or 3 variants
between the groups (p = 0.684), although there was a
clear tendency for these groups to differ in the number
of carriers of specifically Category 1 variants. Even
more interesting is the observation that an excess of
carriers of Category 1 variants was found in the POP group
(n = 5, 10.0 %), rather than in the CAD group (n = 2, 4.8 %)
as one would expect. This suggests that the FH-related
variant rate is higher in populations with higher LDL–
C levels, irrespective of the presence of CAD. It is very
likely that the rate of FH diagnosis would be even
higher in a population selected with an inclusion
criterion of a higher LDL–C cut-off. This is consistent
with suggestions to increase the total cholesterol cut-
offs to improve the diagnostic rate for FH [59]. How-
ever, such conclusions must be validated in larger
cohorts because the majority of similar studies, in-
cluding ours, acquired their data from very small
cohorts and therefore lacked power.
The FH-related mutation detection rate of 7.6 % for
definite FH is slightly higher than but similar to that in a
recently published study in which FH-causing variants
were identified in 2.1 % of unrelated high-risk individ-
uals [60]. Studies in which NGS was used to detect
variants in FH patient populations with defined clinical
criteria reported higher detection rates, ranging from
67 % in clinically defined FH patients to 26 % in possible
FH patients [61]. It is clear that studies with stronger
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inclusion criteria, based on clinical signs of FH or the
presence of a family history, show much higher detec-
tion rates. The recent study by Maglio and colleagues
[62] showed a detection rate of approximately 60 % in
a study group in which all the participants had a
family history of CAD, and 74 % of whom were classi-
fied with definite or probable FH, and 16 % displayed
xanthomas.
A typical drawback of amplicon-based sequencing
methods is the incomplete coverage arising from the
limits of multiplexing. With our approach, 92.1 % of
regions of interest were covered theoretically, whereas
90.7 % were obtained in practice because some ampli-
cons did not produce PCR products. However, the
depth of reads for all the successfully sequenced ampli-
cons was sufficient to cover the expected regions
completely. This can be considered close to optimal
because all the known functional domains were covered
and the regions omitted were mainly untranslated parts
of the genes.
Conclusions
In conclusion, we have shown that NGS-based methods
can be used to detect FH in high-risk individuals and
delivered a definitive diagnosis of FH in 7.6 % of all
subjects in a population who did not meet the defined
clinical criteria for FH. In this study, we also discussed
the possible roles of low-penetrance variants in the
etiology of high LDL–C and the problems associated
with the interpretation of NGS results. It is clear that
additional cascade testing in family members must be
performed in subjects with uncertain variants. Imple-
mentation of the NGS-based approach may increase the
percentage of known cases of FH, a currently underdiag-
nosed disease, and even more importantly, individuals
with milder forms of FH and elevated LDL–C.
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